Collegium Pharmaceutical (COLL) Operating Margin (2016 - 2026)
Collegium Pharmaceutical (COLL) recorded quarterly Operating Margin of 15.97% in Q1 2026, down 46.01% quarter-over-quarter from 29.57% in Q4 2025, and up 376.0% on a YoY basis from 3.35% in Q1 2025.
Collegium Pharmaceutical (COLL) Operating Margin (2016 - 2026) Analysis & Trends
Collegium Pharmaceutical's Operating Margin history runs 11 years deep, the most recent figure standing at 15.97% for Q1 2026.
- In Q1 2026, Operating Margin rose 376.0% year-over-year to 15.97%; the TTM figure through Mar 2026 stood at 23.71% (down 399.0% YoY), while the FY2025 annual figure was 23.01%, down 389.0% from the prior year.
- Operating Margin was 15.97% for Q1 2026 at Collegium Pharmaceutical, down from 29.57% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 437.62% in Q3 2024 to a low of 275.52% in Q1 2022.
- Historically, Operating Margin has averaged 29.85% across 5 years, with a median of 20.95% in 2024.
- The sharpest annual moves came in 2024 and 2025: Operating Margin soared 40469 bps in 2024, then sank 40797 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 9.07% in 2022, then soared by 354 bps to 41.2% in 2023, then plunged by 49 bps to 20.95% in 2024, then soared by 41 bps to 29.57% in 2025, then slumped by 46 bps to 15.97% in 2026.
- The last three Operating Margin figures came in at 15.97% (Q1 2026), 29.57% (Q4 2025), and 29.66% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 20.77% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 23.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -122.23% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -12.88% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Collegium Pharmaceutical | 1.10 Bn | 813.71 Mn | 117.25 Mn | 15.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.97% |
| Dec 31, 2025 | 29.57% |
| Sep 30, 2025 | 29.66% |
| Jun 30, 2025 | 18.67% |
| Mar 31, 2025 | 12.20% |
| Dec 31, 2024 | 20.95% |
| Sep 30, 2024 | 437.62% |
| Jun 30, 2024 | 32.68% |
| Mar 31, 2024 | 34.14% |
| Dec 31, 2023 | 41.20% |
| Sep 30, 2023 | 32.93% |
| Jun 30, 2023 | 26.29% |
| Mar 31, 2023 | 17.01% |
| Dec 31, 2022 | 9.07% |
| Sep 30, 2022 | 16.11% |
| Jun 30, 2022 | 8.99% |
| Mar 31, 2022 | -275.52% |
| Dec 31, 2021 | -89.02% |
| Sep 30, 2021 | 17.95% |
| Jun 30, 2021 | 19.78% |